Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
US8404724B2 · kind B2 · utility
6Cited by
3References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 7, 2007 |
| Grant date | Mar 26, 2013 |
| Priority date | — |
| Expiry date | Nov 15, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.